mighties at the MDA Conference

Next up, at the MDA conference, our booth was ready to welcome existing connections as well as new ones. Over the course of the next three days, we met with over a hundred healthcare professionals, physicians, patients, advocates, and leaders in the biopharma industry. It was truly inspiring to meet so many individuals, all motivated by the same patient-centric mission to improve quality of life and give patients more options and better access. At our stand, we had conversations with physicians which reinforced the need for patient-focused support when potential clinical trials are being investigated. We gave out helpful materials to treating physicians and clinical researchers designed to explain the myTomorrows’ mission, purpose and highlight our relevance within the industry. We showcased our easy-to-use platform through demos, showing how our personalized and streamlined approach empowers both physicians and patients to manage treatment with confidence. We’d like to thank everyone who visited us, your time, expertise and passion was really appreciated.

A key priority for us at the conference was to further our own understanding of current developments and innovations. We joined a series of lectures and workshops, demonstrating cutting edge research advancements and clinical achievements in neuromuscular disease. For me, to be a part of that wider discussion, side by side with so many distinguished guests and leaders, was awe inspiring. I was fascinated by the session led by Barry Byrne MD PhD on Gene Therapy. Put simply, this exploration has the power to change the landscape of therapies for the future, and hugely impact the NMD community. There was a strong focus about Gene Therapy throughout the conference, drawing big crowds. On one occasion, there were so many attendees for a session, a separate room had to set-up for the overflow of interested parties! We learnt about new and emerging therapies, as well as practical considerations for the Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) fields – the learnings from which will no doubt inform our future strategy at myTomorrows. As an organization which prides itself on keeping up to date with the latest tech and treatments, we relentlessly focus on how we can best adapt to ensure patients worldwide have access to the most up to date information on the entire treatment landscape. My time at the conference truly reinforced my belief in the importance and relevance of the myTomorrows mission.